
News|Articles|May 1, 2002
Revised rofecoxib labeling adds GI safety benefit, cardiovascular risk
Merck has issued revised labeling for its COX-2 inhibitor rofecoxib (Vioxx) that incorporate findings from the 8,000-patient VIGOR (Vioxx Gastrointestinal Outcomes Research) study.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
2
What’s New in the Diagnosis and Treatment of Headaches That Ophthalmologists Should Know About? | AAO 2025
3
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
4
El Niño and La Niña Affect Eye Health Too, Not Just Weather | AAO 2025
5